After Obtaining Approval for Its Weight Loss Pill, Is It Off to the Races for Eli Lilly Stock?

Eli Lilly received FDA approval for its GLP-1 pill Foundayo on April 1, potentially expanding its addressable market beyond injectables like Zepbound and Mounjaro. The company’s 2024 revenue rose 45% to $65.2 billion, with Zepbound up 175% to $13.5 billion and Mounjaro nearly doubling to just under $23 billion. While the stock has been boosted by the approval, its valuation remains high at more than 40x trailing earnings, which may temper near-term upside.

Analysis

The approval is less about a near-term revenue step-up and more about expanding Eli Lilly’s addressable market from high-adherence, needle-tolerant patients to the much larger segment that stalls at the delivery mechanism. That matters because GLP-1 adoption is increasingly constrained by persistence rather than awareness; a pill format should improve trial starts, reduce early abandonment, and widen access through primary care and digital prescribing channels. The second-order winner is likely the distribution stack around obesity care — pharmacy benefit managers, mail-order pharmacies, and telehealth refill ecosystems — while injectables face a gradual mix shift rather than an abrupt collapse.

The market may be underestimating how much of the upside is already embedded in the share price. In a name trading at a premium multiple, the hurdle is not whether the product is good, but whether the pill can change the slope of consensus estimates enough to justify multiple expansion. If uptake is merely additive to injectables, the stock can tread water; if oral adoption pulls in previously untreated patients and improves retention, the path to upside is through estimate revisions over the next 2-4 quarters, not an immediate re-rating.

The main risk is not product failure but commercialization friction: payer step edits, obesity access restrictions, and internal cannibalization of higher-priced injectable volume. A second risk is sequencing — the launch could create a classic “sell the approval” event if investors were positioned for an even larger near-term inflection. The contrarian view is that the move may be less overdone than it looks, because the real optionality sits in persistence data and label broadening, which are unlikely to be fully priced until post-launch scripts and refill rates prove out.

Key Decisions for Investors

• Stay long LLY, but use a staggered entry over the next 2-4 weeks rather than chasing the approval pop; upside is likely to come from 2Q/3Q script data, while near-term downside is mostly multiple compression.
• Pair trade: long LLY / short a basket of lower-quality obesity-adjacent biotechs with less differentiated oral pipelines; the thesis is that capital will rotate toward the only platform with both injectables and oral scale.
• Buy LLY Jan-2027 call spreads to express a multi-quarter adoption thesis with defined downside; target a move driven by persistence and payer normalization rather than headline approval momentum.
• Reduce exposure to pure-play delivery-mechanism beneficiaries after the initial enthusiasm; once oral GLP-1 availability is confirmed, the scarcity premium in non-Lilly obesity names should compress.